Filippo Alongi1, Alba Fiorentino1, Berardino De Bari2. 1. Radiation Oncology Department, Sacro Cuore Hospital, Negrar-Verona, Italy. 2. Radiation Oncology Department, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanna, Switzerland.
Abstract
AIM: Radiation therapy (RT) is a standard therapeutic option for prostate cancer (PC). In the last decades, several innovative technology applications have been introduced. 3-Dimensional conformal RT, volumetric/rotational intensity modulated RT associated or not with image-guided RT, are becoming largely diffused in the treatment of PC. BACKGROUND: Considering that PC could have a low α/β ratio, similar to late-reacting normal tissues, it could also be highly responsive to fraction size. Thus, the reduction of the number of fractions and the increase of the dose/fraction seem to be reasonable choices in the treatment of this cancer. This review reported the technology evolution, the radiobiological and the clinical data about the role of extreme hypofractionated RT in the treatment approach of PC patients. MATERIALS AND METHODS: Medline search and analysis of published studies containing key words: prostate cancer, radiotherapy, stereotactic radiotherapy. RESULTS: Recent technological developments, combined with an improved knowledge of the radiobiological models in favor of a high sensitivity of PC to larger fraction sizes are opening a new scenario in its treatment, reporting favorable efficacy and acceptable toxicity, despite short follow-up. CONCLUSION: Thus, thanks to technological improvement and the recent radiobiological data, "extreme hypofractionated RT" has been strongly introduced in the last years as a potential solid treatment option for PC.
AIM: Radiation therapy (RT) is a standard therapeutic option for prostate cancer (PC). In the last decades, several innovative technology applications have been introduced. 3-Dimensional conformal RT, volumetric/rotational intensity modulated RT associated or not with image-guided RT, are becoming largely diffused in the treatment of PC. BACKGROUND: Considering that PC could have a low α/β ratio, similar to late-reacting normal tissues, it could also be highly responsive to fraction size. Thus, the reduction of the number of fractions and the increase of the dose/fraction seem to be reasonable choices in the treatment of this cancer. This review reported the technology evolution, the radiobiological and the clinical data about the role of extreme hypofractionated RT in the treatment approach of PC patients. MATERIALS AND METHODS: Medline search and analysis of published studies containing key words: prostate cancer, radiotherapy, stereotactic radiotherapy. RESULTS: Recent technological developments, combined with an improved knowledge of the radiobiological models in favor of a high sensitivity of PC to larger fraction sizes are opening a new scenario in its treatment, reporting favorable efficacy and acceptable toxicity, despite short follow-up. CONCLUSION: Thus, thanks to technological improvement and the recent radiobiological data, "extreme hypofractionated RT" has been strongly introduced in the last years as a potential solid treatment option for PC.
Authors: Trinitat García Hernández; Aurora Vicedo González; Jorge Pastor Peidro; Juan V Roselló Ferrando; Luis Brualla González; Domingo Granero Cabañero; José López Torrecilla Journal: Rep Pract Oncol Radiother Date: 2013-02-08
Authors: Thomas P Boike; Yair Lotan; L Chinsoo Cho; Jeffrey Brindle; Paul DeRose; Xian-Jin Xie; Jingsheng Yan; Ryan Foster; David Pistenmaa; Alida Perkins; Susan Cooley; Robert Timmerman Journal: J Clin Oncol Date: 2011-04-04 Impact factor: 44.544
Authors: Andrew Loblaw; Patrick Cheung; Laura D'Alimonte; Andrea Deabreu; Alexandre Mamedov; Liying Zhang; Colin Tang; Harvey Quon; Suneil Jain; Geordi Pang; Robert Nam Journal: Radiother Oncol Date: 2013-05-03 Impact factor: 6.280
Authors: Michael Yan; Andre G Gouveia; Fabio L Cury; Nikitha Moideen; Vanessa F Bratti; Horacio Patrocinio; Alejandro Berlin; Lucas C Mendez; Fabio Y Moraes Journal: Nat Rev Urol Date: 2021-08-13 Impact factor: 14.432
Authors: Laura Evangelista; Gianluca Cassarino; Alberto Lauro; Alessandro Morlacco; Matteo Sepulcri; Alex Ahn Li Nguyen; Francesco Ietto; Diego Cecchin; Carmelo Lacognata; Pietro Zucchetta Journal: Abdom Radiol (NY) Date: 2021-05-28